STOCK TITAN

EXELIXIS (EXEL) SEC Filings, Jul-Aug 2025

EXEL NASDAQ

Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.

Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.

Rhea-AI Summary

On August 29, 2025, Exelixis, Inc. announced an internal leadership change: Dana T. Aftab, Ph.D., currently the company’s Executive Vice President, Discovery and Translational Research and Chief Scientific Officer, was appointed Executive Vice President, Research and Development. The filing states information about Dr. Aftab’s background, compensation arrangements, and any related-party transactions is incorporated by reference from the company’s definitive proxy statement on Schedule 14A filed April 16, 2025. Effective the same day, Amy C. Peterson, M.D., concluded her service as Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer, and is entitled to payments under the company’s Change in Control and Severance Benefit Plan, as amended, and applicable law.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
current report
-
Form 10-Q
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.78%
Tags
quarterly report

FAQ

How many EXELIXIS (EXEL) SEC filings are available on StockTitan?

StockTitan tracks 102 SEC filings for EXELIXIS (EXEL), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for EXELIXIS (EXEL)?

The most recent SEC filing for EXELIXIS (EXEL) was filed on November 9, 2026.